A team of researchers from The University of Exeter and Imperial College London have found that certain treatments for inflammatory bowel disease disrupt the body’s ability to respond well to vaccination against COVID-19, resulting in more frequent breakthrough infections.
A study team led by researchers at Queen Mary University of London have found that a third dose of vaccine triggered a detectable immune response in 78% of people with MS who hadn’t responded to their first two doses of vaccine.
The UK Government has joined with a number of organisations representing vaccine manufacturers and the broader biotech and biopharmaceutical industry to commit to the steps necessary to make the so-called 100 Days Mission possible.
New findings from the world’s biggest study on COVID-19 antibodies has shown that two doses of vaccine provide significant short-term protection against COVID-19, but that this protection wanes significantly after six months in people who have not previously been infected.
A new review of available evidence has confirmed that people who have had one or more doses of a COVID-19 vaccine are less likely to develop long COVID than those who are unvaccinated.
The British Society for Immunology has joined forces with the COV-AD study, the UK Primary Immunodeficiency Network and Immunodeficiency UK to hold a free public webinar: Living with immunodeficiency, living with COVID-19.
New data from a team of clinicians in Leeds points to a considerably stronger T-cell response with the AstraZeneca vaccine in a group of people with rheumatoid arthritis, when compared to Pfizer.
The COVID-19 vaccine developed by US biotech company Novavax has been approved for use in the UK after meeting the required safety, quality and effectiveness standards.